S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year
Closing prices for crude oil, gold and other commodities
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Bear Market Funds to Watch This Year
Closing prices for crude oil, gold and other commodities
NASDAQ:EVOK

Evoke Pharma (EVOK) Stock Price, News & Analysis

$0.48
-0.07 (-12.76%)
(As of 04/18/2024 ET)
Today's Range
$0.48
$0.57
50-Day Range
$0.47
$0.75
52-Week Range
$0.42
$2.42
Volume
20,940 shs
Average Volume
24,321 shs
Market Capitalization
$4.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EVOK stock logo

About Evoke Pharma Stock (NASDAQ:EVOK)

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

EVOK Stock Price History

EVOK Stock News Headlines

Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
See More Headlines
Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/19/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EVOK
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-7,790,000.00
Net Margins
-150.43%
Pretax Margin
-150.40%

Debt

Sales & Book Value

Annual Sales
$5.18 million
Book Value
($0.77) per share

Miscellaneous

Free Float
7,479,000
Market Cap
$4.06 million
Optionable
Not Optionable
Beta
0.22
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. David A. Gonyer R.Ph. (Age 60)
    Co-Founder, CEO & Director
    Comp: $666.31k
  • Mr. Matthew J. D'Onofrio MBA (Age 54)
    Co-Founder, President, COO, Secretary & Treasurer
    Comp: $498.12k
  • Dr. Marilyn R. Carlson D.M.D. (Age 76)
    M.D., RAC., Chief Medical Officer
    Comp: $444.99k
  • Mr. Christopher Quesenberry
    Chief Commercial Officer - Gimoti (TM)

EVOK Stock Analysis - Frequently Asked Questions

How have EVOK shares performed in 2024?

Evoke Pharma's stock was trading at $1.0503 at the start of the year. Since then, EVOK stock has decreased by 54.4% and is now trading at $0.4788.
View the best growth stocks for 2024 here
.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 53,400 shares, a decline of 25.9% from the March 15th total of 72,100 shares. Based on an average daily trading volume, of 62,100 shares, the short-interest ratio is presently 0.9 days. Currently, 0.8% of the shares of the company are sold short.
View Evoke Pharma's Short Interest
.

When is Evoke Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our EVOK earnings forecast
.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) issued its quarterly earnings data on Thursday, March, 14th. The specialty pharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $1.68 million during the quarter. Evoke Pharma had a negative trailing twelve-month return on equity of 517.99% and a negative net margin of 150.43%.

When did Evoke Pharma's stock split?

Evoke Pharma shares reverse split on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What guidance has Evoke Pharma issued on next quarter's earnings?

Evoke Pharma issued an update on its FY 2024 earnings guidance on Thursday, March, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14.0 million-$14.0 million, compared to the consensus revenue estimate of $14.0 million.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EVOK) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners